Evaluating Acalabrutinib In The Treatment Of Mantle Cell Lymphoma: Design, Development, And Place In Therapy

Mantle cell lymphoma (MCL) is an incurable intermediate-grade lymphoma representing 5–6% of non-Hodgkin’s lymphomas diagnosed in the United States. The introduction of inhibitors of Bruton’s tyrosine kinase (BTK) into targeted therapy for MCL has significantly improved outcomes in patients with rela...

Descripción completa

Detalles Bibliográficos
Autores principales: Girard, Jennifer, Reneau, John, Devata, Sumana, Wilcox, Ryan A, Kaminski, Mark S, Mercer, Jessica, Carty, Shannon, Phillips, Tycel J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6777435/
https://www.ncbi.nlm.nih.gov/pubmed/31686856
http://dx.doi.org/10.2147/OTT.S155778

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6777435/
https://www.ncbi.nlm.nih.gov/pubmed/31686856
http://dx.doi.org/10.2147/OTT.S155778

Ejemplares similares